70 related articles for article (PubMed ID: 20394679)
1. A complex but promising therapy.
Ronai Z
Pigment Cell Melanoma Res; 2010 Apr; 23(2):151-2. PubMed ID: 20394679
[No Abstract] [Full Text] [Related]
2. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
Sondak VK; Smalley K
Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
[No Abstract] [Full Text] [Related]
3. PAX3 Is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans.
He S; Yoon HS; Suh BJ; Eccles MR
J Invest Dermatol; 2010 May; 130(5):1465-8. PubMed ID: 20107488
[No Abstract] [Full Text] [Related]
4. Identification of a novel nonsense mutation on the Pax3 gene in ENU-derived white belly spotting mice and its genetic interaction with c-Kit.
Guo XL; Ruan HB; Li Y; Gao X; Li W
Pigment Cell Melanoma Res; 2010 Apr; 23(2):252-62. PubMed ID: 20095975
[TBL] [Abstract][Full Text] [Related]
5. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
Nickoloff BJ; Vande Woude G
Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
[No Abstract] [Full Text] [Related]
7. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
8. Increased immunity and BRAF inhibition: Yet another argument for combination therapy?
Smalley KSM
Pharmacol Res; 2016 Nov; 113(Pt A):719-720. PubMed ID: 27392741
[No Abstract] [Full Text] [Related]
9. [Therapeutic approaches in Melanoma - a paradigm for personalized medicine].
Dummer R; Goldinger S; Rinderknecht J; Eggmann N; Felderer L; Braun R; French LE
Praxis (Bern 1994); 2012 Jul; 101(15):955-9. PubMed ID: 22811327
[TBL] [Abstract][Full Text] [Related]
10. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
11. PAX3 across the spectrum: from melanoblast to melanoma.
Medic S; Ziman M
Crit Rev Biochem Mol Biol; 2009 Jun; 44(2-3):85-97. PubMed ID: 19401874
[TBL] [Abstract][Full Text] [Related]
12. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
13. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of late stage melanoma.
Walkington LA; Lorigan P; Danson SJ
BMJ; 2013 Mar; 346():f1265. PubMed ID: 23460638
[No Abstract] [Full Text] [Related]
15. Combination therapies for treating metastatic melanoma.
Tawbi H
Clin Adv Hematol Oncol; 2015 Apr; 13(4):211-4. PubMed ID: 26352577
[No Abstract] [Full Text] [Related]
16. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
17. RAF kinase inhibitors in cancer treatment: like a bull in a China shop?
Robubi A; Waldmann H; Rauh D
Chembiochem; 2010 Aug; 11(12):1645-8. PubMed ID: 20648512
[No Abstract] [Full Text] [Related]
18. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
19. Beyond BRAF in melanoma.
Daud A; Bastian BC
Curr Top Microbiol Immunol; 2012; 355():99-117. PubMed ID: 21826607
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implications of KIT in melanoma.
Postow MA; Carvajal RD
Cancer J; 2012; 18(2):137-41. PubMed ID: 22453014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
